HHS draft policy does not intend to act against compounding six peptides that meet strict conditions
Αυτή η καταχώριση εμφανίζεται στα αγγλικά μέχρι να ενημερωθεί η μετάφρασή της.
The US Department of Health and Human Services announced a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 while the FDA's 503A bulk substances list is developed through rulemaking, but only when every condition in the policy is met. Those conditions include using only the peptide form and route of administration the policy lists, one active ingredient per product, a patient-specific prescription, a raw ingredient made by an FDA-registered manufacturer following good manufacturing practice with a valid certificate of analysis (lab test report), and reporting serious adverse events to the FDA. The notice, published in the Federal Register on 30 October with written comments accepted for two weeks, says the policy is not binding and may be revisited if a safety signal or product quality issue arises. It does not approve these peptides or add them to the list, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.
Πηγές
- 01Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(ανοίγει την πηγή σε νέα καρτέλα)
- 02Draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(ανοίγει την πηγή σε νέα καρτέλα)
- 03HHS to allow compounders to make 6 unapproved peptides(ανοίγει την πηγή σε νέα καρτέλα)
- 04HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending(ανοίγει την πηγή σε νέα καρτέλα)